Novel Immunotherapeutic Avenues for Rheumatoid Arthritis

Trends in Molecular Medicine

Volumn 22, Issue 3, 2016, Pages 214-229

  Semerano, Luca ^a,b,c   Minichiello, Emeline ^b,c   Bessis, Natacha ^a,b   Boissier, Marie Christophe ^a,b,c  

^a MALIBUL and INSERM UMR1125   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 ETHYL 4 (3H IMIDAZO[1,2 A]PYRROLO[2,3 E]PYRAZIN 8 YL) N (2,2,2 TRIFLUOROETHYL) 1 PYRROLIDINECARBOXAMIDE; ABT 122; ANTIRHEUMATIC AGENT; BARICITINIB; BRODALUMAB; BRUTON TYROSINE KINASE INHIBITOR; CD 28SAS; CYTOKINE; FEZAKINUMAB; FILGOTINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 22; IXEKIZUMAB; JANUS KINASE INHIBITOR; MAVRILIMUMAB; NNC 01140006; OFATUMUMAB; SECUKINUMAB; SPEBRUTINIB; T LYMPHOCYTE RECEPTOR; TREGALIZUMAB; UNCLASSIFIED DRUG; USTEKINUMAB;

B LYMPHOCYTE; CELL INTERACTION; DRUG EFFECT; DRUG TARGETING; EXTRACELLULAR MATRIX; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INTRACELLULAR SIGNALING; LOW DRUG DOSE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; STROMA CELL; T LYMPHOCYTE ACTIVATION; TH17 CELL; TREATMENT RESPONSE; ANIMAL; ARTHRITIS, RHEUMATOID; IMMUNOLOGY; PATHOLOGY; PROCEDURES;

ANIMALS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; CYTOKINES; HUMANS; IMMUNOTHERAPY; TH17 CELLS;

EID: 84959105807     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2016.01.005     Document Type: Review

References (116)

1. Boissier M.C., et al. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. J. Autoimmun. 2012, 39:222-228.
2. Yamada R., et al. Peptidylarginine deiminase type 4: identification of a rheumatoid arthritis-susceptible gene. Trends Mol. Med. 2003, 9:503-508.
3. Rantapaa-Dahlqvist S., et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003, 48:2741-2749.
4. Semerano L., et al. Blood vessels, a potential therapeutic target in rheumatoid arthritis?. Joint Bone Spine 2011, 78:118-123.
5. Harre U., et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J. Clin. Invest. 2012, 122:1791-1802.
6. Singh J.A., et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst. Rev. 2009, 4:CD007848.
7. Tak P.P., et al. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum. 1997, 40:217-225.
8. Takemura S., et al. Lymphoid neogenesis in rheumatoid synovitis. J. Immunol. 2001, 167:1072-1080.
9. van de Sande M.G., et al. Presence of lymphocyte aggregates in the synovium of patients with early arthritis in relationship to diagnosis and outcome: is it a constant feature over time?. Ann. Rheum. Dis. 2011, 70:700-703.
10. Pitzalis C., et al. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat. Rev. Immunol. 2014, 14:447-462.
11. Kennedy W.P., et al. Efficacy and safety of pateclizumab (anti-lymphotoxin-alpha) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study). Arthritis Res. Ther. 2014, 16:467.
12. Genovese M.C., et al. Efficacy and Safety of baminercept in the treatment of rheumatoid arthritis (ra) results of the Phase 2b study in the TNF-IR population. Arthritis Rheum. 2009, 60:417.
13. Jones G.W., et al. Interleukin-27 inhibits ectopic lymphoid-like structure development in early inflammatory arthritis. J. Exp. Med. 2015, 212:1793-1802.
14. Raza K., et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res. Ther. 2005, 7:R784-R795.
15. Lefevre S., et al. Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat. Med. 2009, 15:1414-1420.
16. Lee D.M., et al. Cadherin-11 in synovial lining formation and pathology in arthritis. Science 2007, 315:1006-1010.
17. Doody K.M., et al. Targeting phosphatase-dependent proteoglycan switch for rheumatoid arthritis therapy. Sci. Transl. Med. 2015, 7:ra276.
18. Ekwall A.K., et al. The rheumatoid arthritis risk gene LBH regulates growth in fibroblast-like synoviocytes. Arthritis Rheumatol. 2015, 67:1193-1202.
19. Schwager K., et al. Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res. Ther. 2009, 11:R142.
20. Galeazzi M. A Phase Ib clinical trial with dekavil (F8-IL10), an immunoregulatory 'armed antibody' for the treatment of rheumatoid arthritis, used in combination with methotrexate. Arthritis Rheum. 2013, 65:S735.
21. Benham H., et al. Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients. Sci. Transl. Med. 2015, 7:ra287.
22. Morgan M.E., et al. CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis. Arthritis Rheum. 2003, 48:1452-1460.
23. Nguyen L.T., et al. Where FoxP3-dependent regulatory T cells impinge on the development of inflammatory arthritis. Arthritis Rheum. 2007, 56:509-520.
24. Zhou L., et al. Plasticity of CD4+ T cell lineage differentiation. Immunity 2009, 30:646-655.
25. van Amelsfort J.M., et al. CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum. 2004, 50:2775-2785.
26. Samson M., et al. Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum. 2012, 64:2499-2503.
27. Ehrenstein M.R., et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J. Exp. Med. 2004, 200:277-285.
28. McGovern J.L., et al. Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy. Arthritis Rheum. 2012, 64:3129-3138.
29. Nie H., et al. Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-alpha in rheumatoid arthritis. Nat. Med. 2013, 19:322-328.
30. Thiolat A., et al. Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis. Arthritis Rheumatol. 2014, 66:273-283.
31. Flores-Borja F., et al. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:19396-19401.
32. Saleem B., et al. Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?. Ann. Rheum. Dis. 2010, 69:1636-1642.
33. Saadoun D., et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N. Engl. J. Med. 2011, 365:2067-2077.
34. Matsuoka K., et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci. Transl. Med. 2013, 5:ra143.
35. Hartemann A., et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2013, 1:295-305.
36. Hunig T., Dennehy K. CD28 superagonists: mode of action and therapeutic potential. Immunol. Lett. 2005, 100:21-28.
37. Suntharalingam G., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 2006, 355:1018-1028.
38. Tabares P., et al. Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08. Eur. J. Immunol. 2014, 44:1225-1236.
39. Theramab LLC Safety, Safety, Tolerability, Pharmacodynamics and Efficacy Study of TAB08 in Patients With Rheumatoid Arthritis 2015, ClinicalTrials.gov, National Library of Medicine, (https://clinicaltrials.gov/ct2/show/NCT01990157 NLM Identifier: NCT01990157).
40. Becker C., et al. Boosting regulatory T cell function by CD4 stimulation enters the clinic. Front. Immunol. 2012, 3:164.
41. Helling B., et al. A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway. Immunol. Cell Biol. 2015, 93:396-405.
42. van Vollenhoven R., et al. A Phase 2b study evaluating the efficacy and safety of subcutaneously administered tregalizumab in subjects with active rheumatoid arthritis (RA) despite treatment with methotrexate (MTX). Arthritis Rheumatol. 2015, 67. Abstr. 972.
43. Smolen J.S., et al. A Phase 2 study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate. Ann. Rheum. Dis. 2015, 74:76-77.
44. Genovese M.C., et al. One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study. J. Rheumatol. 2014, 41:414-421.
45. Burmester G.R., et al. Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis. Rheumatology (Oxford) 2016, 55:49-55.
46. Burmester G., et al. Association Of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in a cohort of patients with active rheumatoid arthritis: an exploratory Phase 2 biomarker study. Arthritis Rheum. 2013, 65:S736.
47. Genovese M.C. Efficacy and safety after 64 weeks of ixekizumab treatment in a Phase 2 open label extension study in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2013, 72:A616.
48. Pavelka K., et al. A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate. J. Rheumatol. 2015, 42:912-919.
49. Fischer J.A., et al. Combined inhibition of tumor necrosis factor alpha and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody. Arthritis Rheumatol. 2015, 67:51-62.
50. Ahmed G.F., et al. Pharmacokinetics of ABT-122, a dual TNF- and IL-17A-targeted DVD-IG™, after single dosing in healthy volunteers and multiple dosing in subjects with rheumatoid arthritis. Ann. Rheum. Dis. 2015, 74(Suppl. 2):479.
51. Burmester G.R., et al. Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann. Rheum. Dis. 2013, 72:1445-1452.
52. Burmester G., et al. Efficacy and safety/tolerability of mavrilimumab, a human GM-CSFR monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum. 2014, 66:S1231.
53. Burmester G., et al. Long-term safety and efficacy of mavrilimumab, a fully human granulocyte-macrophage colony-stimulating factor receptor-α (GM-CSFR-α) monoclonal antibody, in patients with rheumatoid arthritis (RA). Arthritis Rheumatol. 2015, 67. Abstr. 3111.
54. Huizinga T.W.J., et al. First-in-patient study of namilumab, an anti-GM-CSF monoclonal antibody, in active rheumatoid arthritis: results of the Priora Phase IB study. Ann. Rheum. Dis. 2015, 74:733.
55. Kwok S.K., et al. Interleukin-21 promotes osteoclastogenesis in humans with rheumatoid arthritis and in mice with collagen-induced arthritis. Arthritis Rheum. 2012, 64:740-751.
56. Di Fusco D., et al. IL-21 as a therapeutic target in inflammatory disorders. Expert Opin. Ther. Targets 2014, 18:1329-1338.
57. Rasmussen T.K., et al. Increased interleukin 21 (IL-21) and IL-23 are associated with increased disease activity and with radiographic status in patients with early rheumatoid arthritis. J. Rheumatol. 2010, 37:2014-2020.
58. Gottenberg J.E., et al. Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort. Ann. Rheum. Dis. 2012, 71:1243-1248.
59. Canete J.D., et al. Efficacy and safety of NNC01140006, an Anti-IL-21 monoclonal antibody, in patients with active rheumatoid arthritis. Arthritis Rheum. 2014, 66:S421.
60. Wagner F., et al. Safety and tolerability of NNC01140006, an anti-IL-21 monoclonal antibody, at multiple s.c. dose levels in patients with rheumatoid arthritis. Arthritis Rheum. 2014, 66:S657.
61. Ikeuchi H., et al. Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum. 2005, 52:1037-1046.
62. Kim K.W., et al. Interleukin-22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts. Arthritis Rheum. 2012, 64:1015-1023.
63. Leipe J., et al. Interleukin 22 serum levels are associated with radiographic progression in rheumatoid arthritis. Ann. Rheum. Dis. 2011, 70:1453-1457.
64. Melet J., et al. Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response. Arthritis Rheum. 2013, 65:2783-2790.
65. Anand V., et al. Ofatumumab for rheumatoid arthritis: A Cochrane Systematic Review and meta-analysis. Arthritis Rheumatol. 2015, 67. Abstr. 500.
66. Weinblatt M.E., et al. CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study. Arthritis Rheum. 1995, 38:1589-1594.
67. Genovese M.C. Inhibition of p38: has the fat lady sung?. Arthritis Rheum. 2009, 60:317-320.
68. Akinleye A., et al. Ibrutinib and novel BTK inhibitors in clinical development. J. Hematol. Oncol. 2013, 6:59.
69. Yoshizawa T., et al. Development of a Bruton's tyrosine kinase (Btk) inhibitor, ONO-4059: efficacy in a collagen induced arthritis (CIA) model indicates potential treatment for rheumatoid arthritis (RA). Arthritis Rheum. 2012, 64:1660.
70. Hosoi F., et al. TAS5315, a novel Bruton's tyrosine kinase (BTK) inhibitor, demonstrates potent efficacy in an animal model of rheumatoid arthritis. Arthritis Rheumatol. 2015, 67. Abstr. 2561.
71. Goess C., et al. Efficacy of Abbv-105, a Selective and irreversible inhibitor of Bruton's tyrosine kinase (BTK), in multiple models of inflammation. Arthritis Rheumatol. 2015, 67. Abstr. 1106.
72. Diogo D., et al. TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits. PLoS ONE 2015, 10:e0122271.
73. Karaman M.W., et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008, 26:127-132.
74. Van Rompaey L., et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J. Immunol. 2013, 191:3568-3577.
75. Galien R., et al. Absence of effects of filgotinib on erythrocytes, CD8+ and NK Cells in rheumatoid arthritis patients brings further evidence for the JAK1 selectivity of filgotinib. Arthritis Rheumatol. 2015, 67. Abstr. 2781.
76. Kavanaugh A., et al. Filgotinib (GLPG0634), an oral JAK1 selective inhibitor is effective as monotherapy in patients with active rheumatoid arthritis: results from a Phase 2B dose ranging study. Arthritis Rheumatol. 2015, 67. Abstr. 1049.
77. Westhovens R., et al. Filgotinib (GLPG0634), an oral JAK1 selective inhibitor is effective in combination with methotrexate in patients with active rheumatoid arthritis: results from a Phase 2B dose ranging study. Arthritis Rheumatol. 2015, 67. Abstr. 1048.
78. Kremer J.M. Safety and efficacy of ABT-494, a novel selective JAK1 inhibitor, in patients with active rheumatoid arthritis and inadequate response or intolerance to anti-TNF biologic therapy. Arthritis Rheumatol. 2015, 67. Abstr. 14L.
79. Mahajan S., et al. VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease. J. Pharmacol. Exp. Ther. 2015, 353:405-414.
80. Genovese M.C., et al. VX-509 (Decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheumatol. 2016, 68:46-55.
81. Takeuchi T., et al. Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study. Ann. Rheum. Dis. 2015, Published online December 15, 2015. 10.1136/annrheumdis-2015-208279.
82. Fridman J.S., et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J. Immunol. 2010, 184:5298-5307.
83. Fleischmann R., et al. Baricitinib, methotrexate, or baricitinib plus methotrexate in patients with early rheumatoid arthritis who had received limited or no treatment with disease-modifying anti-rheumatic drugs (DMARDs): Phase 3 trial results. Arthritis Rheumatol. 2015, 67. Abstr. 1045.
84. Kremer J., et al. Response to baricitinib at 4 weeks predicts response at 12 and 24 weeks in patients with rheumatoid arthritis: results from two Phase 3 studies. Arthritis Rheumatol. 2015, 67. Abstr. 1050.
85. Schett G., et al. How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat. Med. 2013, 19:822-824.
86. Emery P., et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008, 372:375-382.
87. van der Bijl A.E., et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum. 2007, 56:2129-2134.
88. Julia A., et al. A genome-wide association study identifies a new locus associated with the response to anti-TNF therapy in rheumatoid arthritis. Pharmacogenomics J. 2015, Published online April 21, 2015. 10.1038/tpj.2015.31.
89. Ferreiro-Iglesias A., et al. Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis. Pharmacogenomics J. 2015, Published online April 21, 2015. 10.1038/tpj.2015.29.
90. Smolen J.S., et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann. Rheum. Dis. 2010, 69:631-637.
91. Nanau R.M., Neuman M.G. Safety of anti-tumor necrosis factor therapies in arthritis patients. J. Pharm. Pharm. Sci. 2014, 17:324-361.
92. Chen X., et al. TNFR2 is critical for the stabilization of the CD4+Foxp3+ regulatory T. cell phenotype in the inflammatory environment. J. Immunol. 2013, 190:1076-1084.
93. Biton J., et al. TNFalpha: activator or inhibitor of regulatory T cells?. Joint Bone Spine 2012, 79:119-123.
94. Zalevsky J., et al. Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J. Immunol. 2007, 179:1872-1883.
95. Kitagaki M., et al. Novel TNF-alpha receptor 1 antagonist treatment attenuates arterial inflammation and intimal hyperplasia in mice. J. Atheroscler. Thromb. 2012, 19:36-46.
96. Shibata H., et al. The therapeutic effect of TNFR1-selective antagonistic mutant TNF-alpha in murine hepatitis models. Cytokine 2008, 44:229-233.
97. McCann F.E., et al. Selective tumor necrosis factor receptor I blockade is antiinflammatory and reveals immunoregulatory role of tumor necrosis factor receptor II in collagen-induced arthritis. Arthritis Rheumatol. 2014, 66:2728-2738.
98. Steeland S., et al. Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1. J. Biol. Chem. 2015, 290:4022-4037.
99. Richter F., et al. Antagonistic TNF receptor one-specific antibody (ATROSAB): receptor binding and in vitro bioactivity. PLoS ONE 2013, 8:e72156.
100. Semerano L., et al. Kinoid of human tumor necrosis factor-alpha for rheumatoid arthritis. Expert Opin. Biol. Ther. 2011, 11:545-550.
101. Le Buanec H., et al. TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:19442-19447.
102. Krieckaert C.L., et al. Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Arthritis Rheum. 2012, 64:3850-3855.
103. Semerano L., et al. Protection from articular damage by passive or active anti-tumour necrosis factor (TNF)-alpha immunotherapy in human TNF-alpha transgenic mice depends on anti-TNF-alpha antibody levels. Clin. Exp. Immunol. 2013, 172:54-62.
104. Durez P., et al. Therapeutic vaccination with TNF-Kinoid in TNF antagonist-resistant rheumatoid arthritis: a phase II randomized, controlled clinical trial. PLoS ONE 2014, 9:e113465.
105. NeoVacs Phase IIb results of TNF-Kinoid in Rheumatoid Arthritis 2015, NeoVacs.
106. Zhou L., et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008, 453:236-240.
107. Korn T., et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007, 448:484-487.
108. Koenders M.I., et al. T cell lessons from the rheumatoid arthritis synovium SCID mouse model: CD3-rich synovium lacks response to CTLA-4Ig but is successfully treated by interleukin-17 neutralization. Arthritis Rheum. 2012, 64:1762-1770.
109. Semerano L., et al. Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs. Expert Opin. Investig. Drugs 2014, 23:979-999.
110. Nowell M.A., et al. Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J. Immunol. 2009, 182:613-622.
111. Montufar-Solis D., et al. Soluble gp130 promotes intestinal epithelial hyperplasia during reovirus infection. Int. J. Exp. Pathol. 2010, 91:276-280.
112. Shi L.Z., et al. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J. Exp. Med. 2011, 208:1367-1376.
113. Schwer B., Verdin E. Conserved metabolic regulatory functions of sirtuins. Cell Metab. 2008, 7:104-112.
114. O'Neill L.A., Hardie D.G. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature 2013, 493:346-355.
115. Scher J.U., et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife 2013, 2:e01202.
116. Zhang X., et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat. Med. 2015, 21:895-905.